Key result
Cardiac contractility modulation decreased hospitalizations from 1.2 to 0.35 per patient-year and yielded 3-year survival comparable to or better than SHFM predictions.
Why the study?
Although CCM improved symptoms, exercise tolerance, and 6-month HF hospitalizations in prior trials, its longer-term impact on hospitalizations and mortality in real-world clinical experience remained to be assessed.
Does cardiac contractility modulation reduce hospitalizations and improve survival in patients with heart failure and LVEF 25-45%?
Cohort (n=140)
Does cardiac contractility modulation reduce hospitalizations and improve survival in patients with heart failure and LVEF 25-45%?
In a real-world registry, cardiac contractility modulation significantly reduced hospitalizations and improved symptoms in patients with heart failure and LVEF 25-45%, with survival comparable to or better than predicted models.
Answers are grounded in this paper and cite their sources.
May reduce hospitalizations in HF with LVEF 25-45%; leaves open need for randomized confirmation.
Aims Cardiac contractility modulation (CCM) improves symptoms and exercise tolerance and reduces heart failure (HF) hospitalizations over 6-month follow-up in patients with New York Heart Association (NYHA) class III or IV symptoms, QRS < 130 ms and 25% ≤ left ventricular ejection fraction (LVEF) ≤ 45% (FIX-HF-5C study). The current prospective registry study (CCM-REG) aimed to assess the longer-term impact of CCM on hospitalizations and mortality in real-world experience in this same population. Methods and results A total of 140 patients with 25% ≤ LVEF ≤ 45% receiving CCM therapy (CCM-REG25-45) for clinical indications were included. Cardiovascular and HF hospitalizations, Minnesota Living with Heart Failure Questionnaire (MLHFQ) and NYHA class were assessed over 2 years. Mortality was tracked through 3 years and compared with predictions by the Seattle Heart Failure Model (SHFM). A separate analysis was performed on patients with 35% ≤ LVEF ≤ 45% (CCM-REG35-45) and 25% ≤ LVEF < 35% (CCM-REG25-34). Hospitalizations decreased by 75% (from 1.2/patient-year the year before, to 0.35/patient-year during the 2 years following CCM, P < 0.0001) in CCM-REG25-45 and by a similar amount in CCM-REG35-45 (P < 0.0001) and CCM-REG25-34. MLHFQ and NYHA class improved in all three cohorts, with progressive improvements over time (P < 0.002). Three-year survival in CCM-REG25-45 (82.8%) and CCM-REG24-34 (79.4%) were similar to those predicted by SHFM (76.7%, P = 0.16; 78.0%, P = 0.81, respectively) and was better than predicted in CCM-REG35-45 (88.0% vs. 74.7%, P = 0.046). Conclusion In real-world experience, CCM produces results similar to those of previous studies in subjects with 25% ≤ LVEF ≤ 45% and QRS < 130 ms; cardiovascular and HF hospitalizations are reduced and MLHFQ and NYHA class are improved. Overall mortality was comparable to that predicted by the SHFM but was lower than predicted in patients with 35% ≤ LVEF ≤ 45%.
No takes yet. Share an insight, caveat, or question.
Anker et al. (2019) conducted a cohort in Heart failure with reduced ejection fraction (n=140). Cardiac contractility modulation vs. Prior year (for hospitalizations) and Seattle Heart Failure Model predictions (for mortality) was evaluated on Hospitalizations (75% decrease, p=<0.0001). Cardiac contractility modulation decreased hospitalizations from 1.2 to 0.35 per patient-year and yielded 3-year survival comparable to or better than SHFM predictions.
Synapse has enriched 10 related papers. Consider them for comparative context: